A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Alendronate on Bone Reception in Postmenopausal Women in Osteoporosis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Alendronate on Bone Reception in Postmenopausal Women in Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top